Patents
1 - N.G. Bazan and J.A.-B. Gomez, “Nuevos derivados de N-acil-4-hidroxifenilamina con propiedades analgésicas y formulaciones farmaceuticas que los contienen,” Patent No. P9501549 (Spain).
2 - N.G. Bazan and J.A.-B. Gomez, “N-acylated 4-hydroxyphenylamine derivatives with analgesic properties and pharmaceutical compositions containing them,” Patent No. 5,554,636; PCT/US96/05456, (WO 96/32940); Canadian application no. 2,218664, European application no.96915332.9, and Japanese application no. B-531944.
3 - N.G. Bazan and J.A.-B. Gomez, “Process for preparing N-acylated 4-hydroxyphenylamine derivatives with analgesic properties,” Patent No. 5,621,110; Div. of 08/426,234, filed 4-21-1995.4 - N.G. Bazan, C.N. Serhan, V.L. Marcheselli, P.K. Mukherjee, S.G. Barreiro, W.J. Lukiw, S. Hong, K. Gronert, and A.E. Musto, “Neuroprotectin D1 protects against cellular apoptosis, stroke damage, Alzheimer's disease and retinal diseases,” pending; Claiming priority form 60/493,110 (01M04) filed August 5, 2003, 60/564,426 (04M12) filed April 22, 2004, and 60/589,445 (05M01) filed July 20, 2004.
5 - J. Hunt, H. Bazan, V.L. Marcheselli, J.A.-B. Gomez, and N.G. Bazan, “A platelet-activating factor antagonist inhibition of angiogenesis and tumor growth induced by basic fibroblast growth factor,” Patent No. 6,979,682; Claiming priority of SN 60/271,286, filed 2-23-01.
6 - N.G. Bazan, C. Sunkel, V.L. Marcheselli and J.A.-B. Gomez, “2,4,6-Trimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid esters as neuroprotective drugs,” Patent No. 6,566,359.
7 - S. Prescott, M. Topham, E.B. Rodriguez de Turco, and N.G. Bazan, “Neuroprotectin by inhibition of diacyglycerol kinase epsilon activity,” Pending, PCT/US2002//008853.
8 - N.G. Bazan and J.A.-B. Gomez, “Synthesis and use of thienotriazolodiazepines,” Patent No. 6,987,105; filed 01/07/2006; Claiming priority from 60/200,420, filed 4-28-2000; US Nat'l stage of PCT/US01/13496 (WO 01/83440).
9 - N.G. Bazan, D. Paul, C. Sunkel, and J.A.-B. Gomez, “Synergistic combinations including N-acylated 4-hydroxyphenylamine derivatives and caffeine,” Patent No. 6,864,271, filed 03-08-2005; See also 7,064,140; Publication No. 2004/0092541; PCT/US2003/036039, filed November 12, 2003, published as International Publication No. WO 20004/043460.
10 - N.G. Bazan, C. Sunkel, D. Paul, and J.A.-B. Gomez, “Synergistic combinations including N-acylated 4-hydroxyphenylamine derivatives with caffeine,” Patent No. 7,064,140, filed 06-20-2006; 10/292,105.
11 - N.G. Bazan, C. Sunkel, J.A.-B. Gomez, and A. Vaccarino, “Analgesic compounds, their synthesis and pharmaceutical compositions containing them,” Patent No. 6,806,291; filed 10-19-2004; PCT/US2004/033609 - published as International Publication No WO 2005/35485 on April 21, 2005.
12 - N.G. Bazan, C. Sunkel, and J.A.-B. Gomez, “5-Lipoxygenase inhibitors: (2-azinylamino) quinone Derivatives,” Patent No. 6,653.311; filed 11-25-2003.
13 - M.A. DeCoster and N.G. Bazan, “Electromagnet probe device,” (pending).
14 - S. Esquenazi, H.E.P. Bazan, and N.G. Bazan, “Topical treatment with NGF and DHA in damaged corneas (was: Topical treatment with nerve growth factor and docosahexaenoic acid in corneal refractive surgery).” Pending; US National Stage of 60/620,459, filed 9-16-05, which claimed priority from 60/620,459, filed 10-19-2004; Int'l applications: Australia SN 2005296212; Canada 2,584,415; Europe (pending).
15 - N.G. Bazan, J.-C. He, and H.E.P. Bazan, “Lipoxin A4 protection for cornea endothelial cells (was Lipoxin A4, Lipoxin A4 epimer, lipoxin A4 analogs, or lipoxin A4 epimer analogs protect the cornea endothelial,” (pending).
16 - N.G. Bazan, “New composition for neuroprotection,” (pending).
17 - N.G. Bazan, “Lipoxin A4 protection for retinal cells,” (pending).
18 - N.G. Bazan and J.-G. Cui, “Therapeutic methods for neuropathic pain,” (pending).
19 - N.G. Bazan, C.N. Serhan, V.L. Marcheselli, P.K. Mukherjee, S.G. Barreiro, W.J. Lukiw, S. Hong, K. Gronert, and A.E. Musto, “Neuroprotectin protects against cellular apoptosis, neuronal stroke damage, Alzheimer's disease, and retinal degeneration,” expired; Canada 2004263164; EPO 04780468.7; Norway 20061039; New Zealand 5456